UniProt P08631 · PDB · AlphaFold · Substrate: Src Substrate peptide · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Dasatinib | 99.9% | 0.1% | 87.97 | 0.699 |
| 2 | Ponatinib | 99.8% | 0.2% | 78.23 | 0.534 |
| 3 | Bosutinib | 99.6% | 0.4% | 87.22 | 0.555 |
| 4 | Repotrectinib | 98.0% | 2.0% | 84.21 | 0.608 |
| 5 | Tivozanib | 97.1% | 2.9% | 92.42 | 0.673 |
| 6 | Ibrutinib | 95.1% | 4.9% | 94.74 | 0.723 |
| 7 | Gilteritinib | 93.1% | 6.9% | 88.97 | 0.506 |
| 8 | Nintedanib | 91.4% | 8.6% | 90.23 | 0.608 |
| 9 | Midostaurin | 90.8% | 9.2% | 78.64 | 0.500 |
| 10 | Cabozantinib | 89.8% | 10.2% | 92.73 | 0.751 |
| 11 | Ripretinib | 89.7% | 10.3% | 92.95 | 0.674 |
| 12 | Vandetanib | 85.9% | 14.1% | 95.74 | 0.723 |
| 13 | Pralsetinib | 83.2% | 16.8% | 93.43 | 0.643 |
| 14 | Erdafitinib | 83.1% | 16.9% | 95.71 | 0.737 |
| 15 | Entrectinib | 82.9% | 17.1% | 93.69 | 0.671 |
| 16 | Brigatinib | 80.9% | 19.1% | 82.96 | 0.513 |
| 17 | Canertinib | 75.3% | 24.7% | 96.49 | 0.671 |
| 18 | Selpercatinib | 73.0% | 27.0% | 96.72 | 0.635 |
| 19 | Nilotinib | 71.5% | 28.5% | 96.49 | 0.765 |
| 20 | Sunitinib | 69.4% | 30.6% | 91.73 | 0.524 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.22
- Epithelial log2(TPM+1): 0.29
- Fold change: -0.06
- Status: No significant change
Selectivity landscape vs inhibition on HCK
Each point is one of the 92 approved drugs; color = inhibition % on HCK.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…